Quick Answer
Allarity Therapeutics, Inc. reported R&D Expense of $6.60 million for fiscal year 2025.
Allarity Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $6.60M | +8.3% |
| 2024 | $6.10M | -14.2% |
| 2023 | $7.10M | +2.5% |
| 2022 | $6.93M | -51.2% |
| 2021 | $14.20M | +236.6% |
| 2020 | $4.22M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.20M | +17.8% | -48.2% |
| June 30, 2025 | $2.32M | +119.4% | +65.4% |
| March 31, 2025 | $1.40M | -35.3% | +37.4% |
| September 30, 2024 | $1.02M | -47.6% | -3.5% |
| June 30, 2024 | $1.06M | -4.3% | -51.2% |
| March 31, 2024 | $2.17M | +52.1% | +11.4% |
| September 30, 2023 | $1.95M | -35.2% | +76.3% |
| June 30, 2023 | $1.10M | -34.8% | -22.6% |
- Allarity Therapeutics, Inc. showed an increase of +8.3% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Allarity Therapeutics, Inc.’s r&d expense has grown by 56.5% (from $4.22 million to $6.60 million).
- The most recent figure is from Allarity Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: